{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T22:40:17Z","timestamp":1790980817406,"version":"4.1.0"},"reference-count":88,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2007,1,1]],"date-time":"2007-01-01T00:00:00Z","timestamp":1167609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2007,1]]},"DOI":"10.1016\/j.pharmthera.2006.08.005","type":"journal-article","created":{"date-parts":[[2006,9,18]],"date-time":"2006-09-18T11:07:06Z","timestamp":1158577626000},"page":"184-196","source":"Crossref","is-referenced-by-count":42,"title":["From pathophysiology to targeted therapy for atherothrombosis: A role for the combination of statin and aspirin in secondary prevention"],"prefix":"10.1016","volume":"113","author":[{"given":"M. John","family":"Chapman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2006.08.005_bib2","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1161\/01.RES.83.10.1015","article-title":"Lipid lowering promotes accumulation of mature smooth muscle cells expressing smooth muscle myosin heavy chain isoforms in rabbit atheroma","volume":"83","author":"Aikawa","year":"1998","journal-title":"Circ Res"},{"key":"10.1016\/j.pharmthera.2006.08.005_bib3","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1161\/01.CIR.103.2.276","article-title":"An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing metalloproteases and tissue factor in vivo and in vitro","volume":"103","author":"Aikawa","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2006.08.005_bib1","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1586\/14779072.3.6.1047","article-title":"Role of clotting factors and fibrin structure in predisposition to atherothrombotic disease","volume":"3","author":"Ajjan","year":"2005","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"10.1016\/j.pharmthera.2006.08.005_bib4","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patients: Antithrombotic Trialists' Collaboration (ATT)","volume":"324","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.pharmthera.2006.08.005_bib5","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1161\/01.ATV.0000012802.69414.A8","article-title":"Fluvastatin reduces tissue factor expression and macrophage accumulaion in carotid lesions of cholesterol-fed rabbits in the absence of lipid lowering","volume":"22","author":"Baetta","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharmthera.2006.08.005_bib6","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2006.08.005_bib7","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/00041433-199310000-00005","article-title":"The role of oxidized low-density lipoprotein in atherogenesis","volume":"4","author":"Berliner","year":"1993","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.pharmthera.2006.08.005_bib8","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/0891-5849(95)02173-6","article-title":"The role of oxidised lipoproteins in atherogenesis","volume":"20","author":"Berliner","year":"1996","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.pharmthera.2006.08.005_bib9","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1053\/euhj.2002.3385","article-title":"Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. The Task Force on the Management of Acute Coronary Syndromes of the European Society of Cardiology","volume":"23","author":"Bertrand","year":"2002","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pharmthera.2006.08.005_bib10","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0002-8703(00)90033-4","article-title":"Statins: effective antiatherosclerotic therapy","volume":"139","author":"Blumenthal","year":"2000","journal-title":"Am Heart J"},{"key":"10.1016\/j.pharmthera.2006.08.005_bib11","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1161\/01.CIR.0000069329.70061.68","article-title":"Vulnerable atherosclerotic plaque: a multifocal disease","volume":"107","author":"Casscells","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2006.08.005_bib12","series-title":"Plasma Lipids and their Role in Disease","article-title":"Atherogenicity of LDL","author":"Chapman","year":"1999"},{"key":"10.1016\/j.pharmthera.2006.08.005_bib13","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1023\/B:THRO.0000036027.39353.70","article-title":"Evolving concepts in the triad of atherosclerosis, inflammation and thrombosis","volume":"17","author":"Corti","year":"2004","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.pharmthera.2006.08.005_bib14","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1161\/01.CIR.103.7.926","article-title":"Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques, Implications for plaque stabilization","volume":"103","author":"Crisby","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2006.08.005_bib15","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0002-9149(99)80580-3","article-title":"Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLAC II)","volume":"75","author":"Crouse","year":"1995","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pharmthera.2006.08.005_bib16","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/S0735-1097(99)00018-2","article-title":"Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile","volume":"33","author":"Dangas","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2006.08.005_bib17","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1055\/s-0038-1649871","article-title":"Thromboxane biosynthesis, neutrophil and coagulation activation in type IIa hypercholesterolemia","volume":"74","author":"Davi","year":"1995","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.pharmthera.2006.08.005_bib18","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1161\/01.CIR.94.8.2013","article-title":"Stability and instability, two faces of coronary atherosclerosis: the Paul Dudley White Lecture","volume":"94","author":"Davies","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2006.08.005_bib19","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/S0195-668X(03)00347-6","article-title":"Executive summary. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice","volume":"24","author":"De Backer","year":"2003","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pharmthera.2006.08.005_bib20","unstructured":"Dictionnaire VIDAL. (2006). Paris, Editions du Vidal."},{"key":"10.1016\/j.pharmthera.2006.08.005_bib21","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1053\/euhj.2001.2610","article-title":"Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries. Principal results from EUROASPIRE II Euro Heart Survey Programme","volume":"22","year":"2001","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pharmthera.2006.08.005_bib22","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)","volume":"285","author":"Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2006.08.005_bib23","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0021-9150(99)00291-9","article-title":"Inhibition of tissue-factor mediated thombin generation by simvastatin","volume":"149","author":"Ferro","year":"2000","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.pharmthera.2006.08.005_bib24","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1161\/01.CIR.87.2.659","article-title":"Aspirin as a therapeutic agent in cardiovascular disease, AHA Medical\/Scientific Statement","volume":"87","author":"Fuster","year":"1993","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2006.08.005_bib25","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S0735-1097(02)03014-0","article-title":"A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease","volume":"41","author":"Gum","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2006.08.005_bib26","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S0140-6736(06)68040-9","article-title":"Aspirin resistance","volume":"367","author":"Hankey","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2006.08.005_bib27","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1056\/NEJMra043430","article-title":"Inflammation, atherosclerosis and coronary artery disease","volume":"352","author":"Hansson","year":"2005","journal-title":"New Engl J Med"},{"key":"10.1016\/j.pharmthera.2006.08.005_bib28","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals. A randomised placebo-controlled trial","volume":"360","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2006.08.005_bib29","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1001\/archinte.164.1.40","article-title":"Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analyses","volume":"164","author":"Hennekens","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.pharmthera.2006.08.005_bib30","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1136\/bmj.330.7499.1059","article-title":"Effect of combinations of drugs on all cause mortality in patients with ischaemic heart disease: nested case-control analysis","volume":"330","author":"Hippisley-Cox","year":"2005","journal-title":"BMJ"},{"key":"10.1016\/j.pharmthera.2006.08.005_bib31","series-title":"Harmonized Clinical Guidelines on Prevention of Atherosclerotic Vascular Disease","year":"2003"},{"key":"10.1016\/j.pharmthera.2006.08.005_bib32","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1161\/01.CIR.98.3.211","article-title":"Increased bioavailability of nitric oxide after lipid-lowering therapy in hypercholesterolemic patients. A randomized, placebo-controlled, double-blind study","volume":"98","author":"John","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2006.08.005_bib33","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S0002-9149(97)00965-X","article-title":"Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)","volume":"81","author":"Jones","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pharmthera.2006.08.005_bib34","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1161\/01.CIR.91.10.2528","article-title":"Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS)","volume":"91","author":"Jukema","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2006.08.005_bib35","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1016\/j.jacc.2004.09.081","article-title":"Volumetric quantitative analysis of tissue characteristics of coronary plaques after statin therapy using three-dimensional integrated backscatter intravascular ultrasound","volume":"45","author":"Kawasaki","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2006.08.005_bib36","first-page":"1305","article-title":"The anti-thrombotic effects of statins","volume":"33","author":"Kearney","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2006.08.005_bib37","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1161\/01.ATV.5.3.293","article-title":"Pulsatile flow and atherosclerosis in the human carotid bifurcation. Positive correlation between plaque location and low oscillating shear stress","volume":"5","author":"Ku","year":"1985","journal-title":"Arteriosclerosis"},{"key":"10.1016\/j.pharmthera.2006.08.005_bib38","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1001\/jama.282.24.2340","article-title":"Effect of statins on risk of coronary disease. A meta-analysis of randomized controlled trials","volume":"282","author":"La Rosa","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2006.08.005_bib87","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1161\/01.STR.0000117574.19517.80","article-title":"Estimating the Cost-Effectiveness of Stroke Units in France compared with Conventional care","volume":"35","author":"Launois","year":"2004","journal-title":"Stroke"},{"key":"10.1016\/j.pharmthera.2006.08.005_bib39","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1093\/eurheartj\/ehi733","article-title":"Economic burden of cardiovascular diseases in the enlarged European Union","volume":"27","author":"Leal","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pharmthera.2006.08.005_bib40","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0008-6363(00)00247-9","article-title":"Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: new concepts for cardiovascular disease","volume":"49","author":"Lefer","year":"2001","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.pharmthera.2006.08.005_bib41","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.mehy.2005.06.035","article-title":"Rebound phenomenon of inflammatory response may be a major mechanism responsible for increased cardiovascular events after abrupt cessation of statin therapy","volume":"66","author":"Li","year":"2006","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.pharmthera.2006.08.005_bib42","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1161\/CIRCULATIONAHA.105.537878","article-title":"Pathophysiology of coronary artery disease","volume":"111","author":"Libby","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2006.08.005_bib43","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/35025203","article-title":"Atheroscler","volume":"407","author":"Lusis","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2006.08.005_bib44","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/sj.bjp.0703407","article-title":"Apoptosis in the vasculature: mechanisms and functional importance","volume":"130","author":"Mallat","year":"2000","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2006.08.005_bib45","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1161\/01.CIR.101.2.207","article-title":"Current perspectives on statins","volume":"101","author":"Maro","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2006.08.005_bib46","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1161\/01.STR.0000174289.34110.b0","article-title":"Intensive treatment with atorvastatin reduces inflammation in mononuclear cells and human atherosclerotic lesions in one month","volume":"36","author":"Martin-Ventura","year":"2005","journal-title":"Stroke"},{"issue":"suppl S","key":"10.1016\/j.pharmthera.2006.08.005_bib47","doi-asserted-by":"crossref","first-page":"79S","DOI":"10.1016\/S0735-1097(02)02831-0","article-title":"Short-and long-term oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention","volume":"41","author":"Mehta","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2006.08.005_bib88","doi-asserted-by":"crossref","first-page":"603","DOI":"10.2165\/00019053-200017060-00006","article-title":"Costs for Acute myocardial Infarction in a tertiary Care Centre and nationwide in France","volume":"17","author":"Montagne","year":"2000","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.pharmthera.2006.08.005_bib48","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1056\/NEJM200106283442609","article-title":"Statins and the acute-phase response","volume":"344","author":"Munford","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2006.08.005_bib49","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0167-5273(00)00439-3","article-title":"Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia","volume":"77","author":"Musial","year":"2001","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.pharmthera.2006.08.005_bib50","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1161\/01.CIR.0000087480.94275.97","article-title":"From vulnerable plaque to vulnerable patient. A call for new definitions and risk assessment strategies: part I","volume":"108","author":"Naghavi","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2006.08.005_bib51","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0092-8674(00)81574-3","article-title":"Oxidised LDL regulates macrophage gene expression through ligand activation of PPAR","volume":"93","author":"Nagy","year":"1998","journal-title":"Cell"},{"issue":"suppl 8A","key":"10.1016\/j.pharmthera.2006.08.005_bib52","doi-asserted-by":"crossref","first-page":"27S","DOI":"10.1016\/S0002-9343(02)01087-2","article-title":"Who is at risk for atherosclerotic disease? Lessons from intravascular ultrasound","volume":"112","author":"Nissen","year":"2002","journal-title":"Am J Med"},{"issue":"12A","key":"10.1016\/j.pharmthera.2006.08.005_bib53","first-page":"22S","article-title":"Halting the progression of atherosclerosis with intensive lipid lowering: results from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial","volume":"118","author":"Nissen","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pharmthera.2006.08.005_bib54","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1001\/jama.295.13.jpc60002","article-title":"Effect of very high-intensity statin therapy on regression of coronary atherosclerosis. The ASTEROID trial","volume":"295","author":"Nissen","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2006.08.005_bib55","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1161\/01.ATV.15.2.247","article-title":"Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia","volume":"15","author":"Notarbartolo","year":"1995","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharmthera.2006.08.005_bib56","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1161\/01.CIR.95.5.1126","article-title":"Simvastatin, an HMG-coenzyme A reductase inhibitor improves endothelial function within 1\u00a0month","volume":"95","author":"O'Driscoll","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2006.08.005_bib57","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1056\/NEJMra052717","article-title":"Low-dose aspirin for the prevention of atherothrombosis","volume":"353","author":"Patrono","year":"2005","journal-title":"N Engl J Med"},{"issue":"8B","key":"10.1016\/j.pharmthera.2006.08.005_bib58","doi-asserted-by":"crossref","first-page":"45H","DOI":"10.1016\/S0002-9149(97)00820-5","article-title":"The treatment gap in coronary artery disease and heart failure: community standards and the post-discharge patient","volume":"80","author":"Pearson","year":"1997","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pharmthera.2006.08.005_bib59","series-title":"European Cardiovascular Disease Statistics","author":"Petersen","year":"2005"},{"key":"10.1016\/j.pharmthera.2006.08.005_bib60","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/0735-1097(95)00301-0","article-title":"Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events","volume":"26","author":"Pitt","year":"1995","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2006.08.005_bib61","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0021-9150(00)00397-X","article-title":"Statins and cardiovascular disease: the multiple effects of lipid-lowering therapy by statins","volume":"153","author":"Rauch","year":"2000","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.pharmthera.2006.08.005_bib62","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJM199704033361401","article-title":"Inflammation, aspirin and the risk of cardiovascular disease in apparently healthy men","volume":"336","author":"Ridker","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2006.08.005_bib63","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1161\/01.CIR.98.9.839","article-title":"Inflammation, pravastatin and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators","volume":"98","author":"Ridker","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2006.08.005_bib64","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1161\/01.CIR.100.3.230","article-title":"Long-term effects of pravastatin on plasma concentration of C-reactive protein: the Cholesterol and Recurrent Events (CARE) Investigators","volume":"100","author":"Ridker","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2006.08.005_bib65","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","article-title":"The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators","volume":"335","author":"Sacks","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2006.08.005_bib66","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/S0140-6736(02)11600-X","article-title":"Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial","volume":"360","author":"Shepherd","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2006.08.005_bib67","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1161\/01.ATV.0000032033.39301.6A","article-title":"Statin therapy in acute coronary syndromes. Mechanistic insight into clinical benefit","volume":"22","author":"Sposito","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharmthera.2006.08.005_bib68","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1161\/01.CIR.92.5.1355","article-title":"A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis. American Heart Association","volume":"92","author":"Stary","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2006.08.005_bib69","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2165\/00129784-200505060-00007","article-title":"The role of the platelet in the pathogenesis of atherothrombosis","volume":"5","author":"Steinhubl","year":"2005","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.pharmthera.2006.08.005_bib70","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/S0735-1097(99)00023-6","article-title":"Inhibition of thrombin generation by simvastatin and lack of additive effects of aspirin in patients with marked hypercholesterolemia","volume":"33","author":"Szczeklik","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2006.08.005_bib71","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0021-9150(03)00158-8","article-title":"Relationship between effects of statins, aspirin and angiotensin II modulators on high-sensitive C-reactive protein levels","volume":"169","author":"Takeda","year":"2003","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.pharmthera.2006.08.005_bib72","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1161\/hq1101.098486","article-title":"Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors","volume":"21","author":"Takemoto","year":"2001","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharmthera.2006.08.005_bib74","series-title":"L'ath\u00e9roscl\u00e9rose: Physiopathologie, Diagnostics, Th\u00e9rapeutiques","first-page":"245","article-title":"Pathogen\u00e8se de l'ath\u00e9roscl\u00e9rose : th\u00e9ories et m\u00e9canismes","author":"Tedgui","year":"2003"},{"key":"10.1016\/j.pharmthera.2006.08.005_bib73","first-page":"162","article-title":"Atheroscl\u00e9rose et Inflammation","volume":"14","author":"Tedgui","year":"2001","journal-title":"Med Sci"},{"key":"10.1016\/j.pharmthera.2006.08.005_bib75","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199811053391902","article-title":"Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels","volume":"339","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2006.08.005_bib76","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0092-8674(00)81575-5","article-title":"PPAR\u03b3 promotes monocyte-macrophage differentiation and uptake of oxidised LDL","volume":"93","author":"Tontonoz","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2006.08.005_bib77","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1161\/01.CIR.95.3.594","article-title":"Tissue factor modulates the thrombogenicity of human atherosclerotic plaques","volume":"95","author":"Toschi","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2006.08.005_bib78","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1161\/01.ATV.18.5.677","article-title":"Laminar shear stress: mechanisms by which endothelial cells transduce an atheroprotective force","volume":"18","author":"Traub","year":"1998","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharmthera.2006.08.005_bib79","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0195-668X(02)00618-8","article-title":"Task Force Report. Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology","volume":"24","author":"Van de Werf","year":"2003","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pharmthera.2006.08.005_bib80","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S0140-6736(96)05190-2","article-title":"Statins do more than just lower cholesterol","volume":"348","author":"Vaugham","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2006.08.005_bib81","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1161\/01.ATV.15.5.551","article-title":"The response-to-retention hypothesis of early atherogenesis","volume":"15","author":"Williams","year":"1995","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharmthera.2006.08.005_bib82","series-title":"Global Burden of Disease","author":"World Health Organization","year":"2002"},{"key":"10.1016\/j.pharmthera.2006.08.005_bib83","series-title":"The Report of the Second Meeting of the Global Forum on Noncommunicable Disease Prevention and Control. Shanghai, China, 4\u20136 November 2002","author":"World Health Organization","year":"2002"},{"key":"10.1016\/j.pharmthera.2006.08.005_bib84","unstructured":"World Health Organization. (2005). Active Ageing. A policy framework. WHO\/NMH\/NPH\/02.8. Available from http:\/\/www.who.int\/gb\/ebwha\/pdf_files."},{"key":"10.1016\/j.pharmthera.2006.08.005_bib85","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1161\/01.CIR.99.8.993","article-title":"Oxidized low-density lipoprotein regulates matrix metalloproteinase-9 and its tissue inhibitor in human monocyte-derived macrophages","volume":"99","author":"Xu","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2006.08.005_bib86","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0140-6736(04)17018-9","article-title":"Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study","volume":"364","author":"Yusuf","year":"2004","journal-title":"Lancet"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725806001537?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725806001537?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,21]],"date-time":"2019-04-21T01:52:19Z","timestamp":1555811539000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725806001537"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1]]},"references-count":88,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,1]]}},"alternative-id":["S0163725806001537"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2006.08.005","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2007,1]]}}}